Creative Biolabs is one of the leading antibody generation and development service providers. We specialize in the generation of antibodies for R&D, diagnostic, and therapeutic applications. Especially, we offer customized high-quality in vitro diagnostic (IVD) antibody development services against different sepsis biomarkers, such as thrombin-antithrombin complex (TAT).
Sepsis and DIC
Sepsis represents the systemic inflammatory response to infection. Severe sepsis is defined as sepsis associated with organ dysfunction. Severe sepsis is associated with the concomitant activation of the inflammatory and coagulation cascades. Studies have reported that sepsis is frequently complicated with coagulopathy. The severity of sepsis-associated coagulopathy is variable, ranging from subclinical abnormalities that are detectable by a mild decrease in platelet count and prolongation of global clotting times, to severe forms of coagulopathy or disseminated intravascular coagulation (DIC). Currently, the overt DIC criteria of the International Society on Thrombosis and Haemostasis (ISTH) are the diagnostic standard for severe coagulopathy in sepsis. The ISTH overt DIC criteria use simple laboratory tests such as platelet count, elevated fibrin-related marker, and prolonged prothrombin time for scoring. However, these tests are less satisfying for early diagnosis of severe coagulopathy in patients with sepsis. Hemostatic biomarkers are therefore being developed and assessed for an early diagnosis of DIC.
Fig. 1 Pathophysiological mechanisms of sepsis.1, 2
TAT for Sepsis Prognosis & Diagnosis
TAT, a marker of thrombin generation and coagulation activation, has been found to be one of the early diagnostic markers for severe coagulopathy and DIC. For instance, Koyama et al. (2014) evaluated 14 plasma biomarkers (e.g., TAT, soluble fibrin, protein C) for association with subsequent development of overt DIC in patients with sepsis. Their findings showed that coagulopathy was frequently observed in the initial phase of sepsis, and severe coagulation and fibrinolytic abnormalities were strongly associated with subsequent development of overt DIC. The activity of TAT, plasminogen activator inhibitor (PAI)-1 and protein C on ICU admission were the best combination to discriminate between patients with and without overt DIC. In terms of predicting mortality, only TAT and PAI-1 were significant predictors of 28-day mortality at the time of ICU admission.
IVD Antibody Development Services for TAT
Since TAT is proposed to be a reliable marker to identify patients with severe coagulopathy early in the course of sepsis, antibodies could be developed against this marker to help early clinical diagnosis. Creative Biolabs provides IVD antibody development services against different sepsis biomarkers, including TAT, to help researchers in the development of different immunoassays (e.g., ELISAs, immunohistochemistry, Western blot, immunochromatography assay) and IVD kits.
To better suit the needs of our valued clients, Creative Biolabs provides full-scale customized IVD antibody development services at the most competitive prices. Supported by our highly specialized scientists and advanced platform, we are confident in providing the best services and products. If you are interested in our services, contact us for more information.
References
For Research Use Only.
